Temporomandibular pain: pooled benefits with reporting conflicts · Review · 2026
Does shockwave help jaw joint pain and mouth opening?
In this review, jaw pain eased more with shockwave than with comparison treatments across 17 trials (1,036 people), and the mouth opened about 4 mm wider on average. Scores for overall jaw function ended about the same in both groups.
Eased jaw pain more than comparison care- trials in the pain results
- 17
- people in the pain results
- 1,036
- results pooled: pain, mouth opening and jaw function
- 3
Good to know: Treatments and comparisons varied between trials.
Chen L, Luo Y, Zhang L, et al. Front Rehabil Sci, 2026 · Read the paper ↗
How this study worked
What happened
- studies
- 17
- people
- 1,036
- Compared with
- Active rehabilitation, medicines, sham treatment or no treatment, depending on the trial
Jaw pain compared with other treatments
Standardised difference across pain scales · below zero means less pain with shockwave
Show the numbers
| Difference (standardised difference (no units)) | likely range | |
|---|---|---|
| Jaw pain | −1.28 | −1.96 to −0.61 |
What the trials used
- Protocol reporting
- ESWT alone or combined with physical therapy, medicines or traditional Chinese interventions. Main PDF does not supply a complete study-by-study device/energy/session table; no pooled regimen can be recommended.
Who took part
People with jaw joint and jaw muscle disorders (temporomandibular disorders), mostly in single-centre trials in China.
Side effects
The authors mention brief redness or discomfort.
All the numbers and the full appraisal
The results, in numbers.
Reported total 1,150 participants; pain 17 studies/1,036, opening 12/823, dysfunction 13/850. Mostly Chinese single-centre trials. Sex totals 509+601=1,110, not 1,150, and Table 1 reverses labels. Reference 40 is 2016 despite stated 2018–2025 inclusion range.
Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS)1 reported outcome
Pain: forest-plot SMD
Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) standard deviations
ESWT versus study-specific controls
17 studies · 1,036 participants in this estimate · I²=95%
Pooled random-effects estimate
Forest plot explicitly uses SMD, not VAS points; text/table mislabel MD. Plot p=.0002 conflicts with text p<.00001.
Analysis details and source
Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.
Maximal mouth opening1 reported outcome
Maximal mouth opening
Maximal mouth opening mm
ESWT versus study-specific controls
12 studies · 823 participants in this estimate · I²=97%
Pooled random-effects estimate
Positive difference means greater opening in ESWT; printed favors-axis labels are inconsistent with this direction.
Analysis details and source
Source-reported random-effects estimate; no recalculation.
Dysfunction index1 reported outcome
Dysfunction index
Dysfunction index index units
ESWT versus study-specific controls
13 studies · 850 participants in this estimate · I²=99%
Pooled random-effects estimate
Interval crosses zero; no clear dysfunction benefit despite pain/opening signals.
Analysis details and source
Source-reported random-effects estimate; no recalculation.
Exploratory duration subgroups1 reported outcome
Exploratory duration subgroups
Qualitative finding
Table 2 reports ≤2 weeks −0.79 [−1.38, −0.20] versus ≥4 weeks −1.79 [−2.09, −1.49], subgroup p = 0.003. Metric is labelled MD but main pain figure is SMD; do not prescribe duration from this ecological comparison. Table 2 subgroup interactions were null for shock count (p = 0.82) and sex composition (p = 0.79).
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
ESWT alone or combined with physical therapy, medicines or traditional Chinese interventions. Main PDF does not supply a complete study-by-study device/energy/session table; no pooled regimen can be recommended.
Discussion describes transient redness/discomfort, but the review gives no systematic adverse-event counts or pooled harm analysis. A favorable safety conclusion exceeds the presented safety data.
Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.
Source-linked critical reading
clinical synthesis
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.
Some pooled results favor waves for pain and mouth opening, but jaw dysfunction did not clearly improve. Reporting problems mean the size and reliability of benefit remain uncertain.
Does ESWT improve pain, mouth opening and dysfunction in temporomandibular disorders?
Systematic review/meta-analysis of 18 trials, searched seven databases through December 2025. Random-effects pooling combined differing treatments and controls. Methods call bias assessment RoB2, while Results and figures use seven older-style domains and unclear-risk terminology.
Reported total 1,150 participants; pain 17 studies/1,036, opening 12/823, dysfunction 13/850. Mostly Chinese single-centre trials. Sex totals 509+601=1,110, not 1,150, and Table 1 reverses labels. Reference 40 is 2016 despite stated 2018–2025 inclusion range.
ESWT alone or combined with physical therapy, medicines or traditional Chinese interventions. Main PDF does not supply a complete study-by-study device/energy/session table; no pooled regimen can be recommended.
Active rehabilitation, drugs, sham or no intervention were allowed. Combining add-on and replacement contrasts obscures how much benefit is specifically attributable to waves.
Pain VAS/NRS, maximal interincisal opening and dysfunction index after treatment. Figure 4 reports standardized mean differences for pain, although text calls them MD on 0–10 VAS. Keep the forest-plot metric rather than treating −1.28 as VAS points.
Figure 4: pain SMD −1.28 (95% CI −1.96 to −0.61), p = 0.0002, I² = 95%; text incorrectly prints p < 0.00001. Opening MD 3.76 mm (1.52 to 5.99), p = 0.001, I² = 97%; Figure 5 favors labels oppose higher-is-better direction. Dysfunction MD −0.05 (−0.13 to 0.03), p = 0.22, I² = 99%: no clear difference.
Discussion describes transient redness/discomfort, but the review gives no systematic adverse-event counts or pooled harm analysis. A favorable safety conclusion exceeds the presented safety data.
Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.
The review suggests possible short-term pain/opening benefits, but source inconsistencies prevent confident point-scale interpretation or a preferred-treatment recommendation. Null dysfunction matters for daily function.
Reconcile every trial, metric and figure direction against original data, report reproducible doses, separate sham and active-control contrasts, and use prespecified long-term outcomes and GRADE.
Read the original article.
Extracorporeal shock wave therapy for temporomandibular disorders: efficacy on pain, maximal mouth opening, and dysfunction—a meta-analysis of randomized controlled trials
Chen L, Luo Y, Zhang L, Zhang X, Chen Y, Hu D. · Front Rehabil Sci · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →